Forte Biosciences Income Statement (2016-2026) | FBRX

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
3.52M5.66M1.35M0.69M1.03M1.38M2.49M4.79M7.14M6.37M3.57M4.32M5.59M5.72M5.08M12.54M8.47M15.05M21.59M20.32M
Selling, General & Administrative (Quarter)
2.22M2.04M1.95M1.82M1.99M2.04M2.45M2.07M1.90M3.85M2.81M3.45M7.08M2.76M2.12M3.43M2.96M3.18M2.83M1.97M
Other Operating Expenses (Quarter)
0.03M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M
Operating Expenses (Quarter)
5.75M7.70M3.30M2.51M3.02M3.42M4.94M6.86M9.03M10.22M6.38M7.80M12.82M8.63M7.35M16.12M11.58M18.38M24.57M22.44M
Operating Income (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-16.12M-11.58M-18.38M31.73M-22.44M
EBIT (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-16.12M-11.58M-18.38M31.73M-22.44M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)
-0.07M-0.05M-0.04M-0.05M-0.01M0.02M-0.10M0.10M0.14M0.26M-0.61M0.38M0.31M0.24M-1.12M0.47M0.33M0.70M-1.90M0.68M
Non Operating Income (Quarter)
-0.07M-0.05M-0.04M-0.05M-0.01M0.02M-0.10M0.10M0.14M0.26M-0.61M0.38M0.31M0.24M0.20M0.47M0.33M0.70M-1.90M0.68M
Net income details
EBT (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-15.66M-11.58M-18.38M31.73M-21.76M
Tax Provisions (Quarter)
0.37M
Profit After Tax (Quarter)
-5.81M-7.75M-3.34M-2.57M-3.04M-3.40M-4.88M-6.75M-8.90M-9.96M-5.87M-7.42M-12.51M-8.39M-7.16M-15.66M-11.25M-17.68M-24.79M-22.14M
Income from Continuing Operations (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-15.66M-11.58M-18.38M31.73M-22.14M
Consolidated Net Income (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-15.66M-11.58M-18.38M31.73M-22.14M
Income towards Parent Company (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-15.66M-11.58M-18.38M31.73M-22.14M
Net Income towards Common Stockholders (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M21.80M-15.66M-11.58M-18.38M31.73M-22.14M
Additional items
EPS (Basic) (Quarter)
-0.43-0.54-0.21-0.17-0.21-0.18-0.24-0.32-0.42-6.57-0.95-4.03-6.78-4.543.18-1.37-0.96-0.99-1.45-1.24
EPS (Weighted Average and Diluted) (Quarter)
-0.43-0.54-0.21-0.17-0.21-0.18-0.24-0.32-0.42-6.57-0.95-4.03-6.78-4.543.18-1.37-0.96-0.99-1.45-1.24
Shares Outstanding (Weighted Average) (Quarter)
13.43M13.70M13.97M14.76M14.76M16.16M17.38M21.01M21.03M1.45M9.69M9.69M9.69M0.39M5.00M4.82M5.37M5.30M4.88M3.96M
Shares Outstanding (Diluted Average) (Quarter)
13.43M14.24M13.97M14.76M14.76M16.16M17.38M21.01M21.03M
EBITDA (Quarter)
-5.75M-7.70M-3.30M-2.51M-3.04M-3.40M-4.88M-6.75M-8.89M-9.96M-5.86M-7.43M-12.52M-8.38M-7.14M-15.67M-11.25M-17.69M31.73M-22.44M
Interest Expenses (Quarter)
Tax Rate (Quarter)
-1.71%